Saniona's new CMO to BioStock: "More deals are definitely on the horizon"
Saniona has appointed Pierandrea Muglia, M.D., as Chief Medical Officer, bringing over three decades of expertise from large international pharmaceutical companies, biotech and neuroscience research. A board member since 2023, Muglia has seen Saniona's pipeline grow and its partnerships, like the $610 million deal with Acadia Pharmaceuticals, thrive. Now, he'll steer the company's clinical and regulatory efforts as it prepares three candidates for phase II trials. We talked with Muglia to explore his visions.
Read the full interview at biostock.se:
https://www.biostock.se/en/2025/03/sanionas-new-cmo-more-deals-are-definitely-on-the-horizon/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/